Pharma R&D Center Stage As Japan Preps For New Agency
This article was originally published in PharmAsia News
Japan’s government is gearing up for major changes in how it funds basic pharma and medtech R&D, with a new agency due to be set up next March as part of a broader health care policy initiative approved earlier this year.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.